FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe response	5)																	
1. Name and Address of Reporting Person* MOTT DAVID M					2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]						5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner							
(Last) (First) (Middle) 1954 GREENSPRING DRIVE, SUITE 600						3. Date of Earliest Transaction (Month/Day/Year) 09/07/2018						-	Office	r (give title belo	ow)	Other (specify	below)		
(Street)					4. If	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
TIMONIUM, MD 21093 (City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)		Executi any	A. Deemed xecution Date, if		Code		4. Securities Acquired (A) of Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownershi Form: Direct (D)	of Ind Bene Owne	Beneficial Ownership					
							C	ode	V	Amount		A) or D)	Price				or Indirec (I) (Instr. 4)	t (Instr	r. 4)
	Shares wi value of 0. share (1)		09/07/2	2018				P		3,000,00	0		§ 1.6667 <u>2)</u>	82,978	3,668 (1)		I	See Note	
Ordinary Shares with a nominal value of 0.001 09/07/2018 GBP per share (4)					P		12,000,0 (4)	00		§ 1.6667 <u>2)</u>	12,000,000 (4)		I	See Note					
Reminder:	Report on a s	separate lin	e for each		l - Deriv	rative Secu	ritie	s Acq	F c tl	Persons who ontained in the form disposed	no res n this splay	fori	m are current	not requ tly valid	ired to res	formation spond unle trol numbe	ss	C 1474	(9-02)
4 50 1		l	. 1				war 5.			ons, conver					0.77.		2 4 2		
Derivative Conversion Date			ay/Year)	any	Date, if	4. Transaction Code (Instr. 8)			r a (ive ies ed ed s,	5. Date Exer and Expirati Month/Day	on Da	te	Amou Under Secur	rlying ities . 3 and	8. Price of Derivative Security (Instr. 5)	9. Number Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form of Deriva Securi Direct or Indi	rship of Bottive O (I) (I) rect	1. Natur f Indirec Beneficia Dwnershi Instr. 4)
						Code	V (.	A) (Date Exercisable	Expii Date	ration	Title	Amount or Number of Shares					

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
MOTT DAVID M 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM, MD 21093	X	X					

Signatures

/s/ Sasha Keough, attorney-in-fact	09/10/2018	

**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates (1) 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.
- (2) The price reported in Column 4 of \$1.6667 per ordinary share is a price derived from the price of \$10.00 per ADS, divided by six.
- The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general (3) partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the
- (3) partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Reporting Person has no pecuniary interest.
- The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates (4) 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.
- The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.